L
Lilly Yuen
Researcher at Royal Melbourne Hospital
Publications - 48
Citations - 1218
Lilly Yuen is an academic researcher from Royal Melbourne Hospital. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 18, co-authored 44 publications receiving 1126 citations. Previous affiliations of Lilly Yuen include The Chinese University of Hong Kong & University of Melbourne.
Papers
More filters
Journal ArticleDOI
SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.
Lilly Yuen,Anna Ayres,Margaret Littlejohn,Danielle Colledge,Andrew Edgely,William J Maskill,Stephen Locarnini,Angeline Bartholomeusz +7 more
TL;DR: SeqHepB will enable virologists and physicians to individualise patient management, cope with the explosion of antiviral associated HBV mutations, and to conduct cross-sectional retrospective or prospective studies on HBV-infected individuals during therapy.
Journal ArticleDOI
A Divergent Hepatitis D-Like Agent in Birds.
Michelle Wille,Hans Jurgen Netter,Margaret Littlejohn,Lilly Yuen,Mang Shi,John-Sebastian Eden,Marcel Klaassen,Edward C. Holmes,Aeron C. Hurt +8 more
TL;DR: Using meta-transcriptomics, the genome of a novel HDV-like agent in ducks is identified and secondary structures that were shared with HDV, including self-complementarity and ribozyme features are revealed.
Journal ArticleDOI
Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.
A Ayres,Lilly Yuen,Kathy Jackson,S. Manoharan,A. Glass,Maria Maley,W. Yoo,Seung Pyo Hong,Sangcheol Kim,Fabio Luciani,D. S. Bowden,Julianne Bayliss,Miriam T. Levy,Stephen Locarnini +13 more
TL;DR: UDPS showed that LMV therapy resulted in increased viral quasispecies diversity and positive selection of HBV variants with reverse transcriptase amino acid substitutions at sites associated with primary LMV resistance in four women, and drug‐resistant viral variants emerged.
Journal ArticleDOI
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors.
Alexander J. Thompson,Anna Ayres,Lilly Yuen,Angeline Ingrid Bartholomeusz,D. Scott Bowden,David Iser,Robert Y M Chen,B. Demediuk,Gideon Shaw,Sally Bell,Katrina J R Watson,Stephen Locarnini,Paul V. Desmond +12 more
TL;DR: In this paper, a Cox proportional hazards model was used to determine variables independently predicting for the early onset of lamivudine resistance, with rate ratios of 4.93 (95% confidence interval [CI]: 1.32-18.5, P < 0.05).
Journal ArticleDOI
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Jennifer Audsley,N Arrifin,Lilly Yuen,Anna Ayres,Suzanne M. Crowe,Suzanne M. Crowe,Suzanne M. Crowe,Angeline Ingrid Bartholomeusz,Stephen Locarnini,Anne M Mijch,Anne M Mijch,Sharon R Lewin,Sharon R Lewin,Sharon R Lewin,Joe Sasadeusz,Joe Sasadeusz +15 more
TL;DR: The aim of the study was to identify and characterize hepatitis B virus polymerase gene mutations associated with ongoing HBV replication in HIV/HBV‐coinfected individuals receiving tenofovir (TDF).